Frankie A. Colosimo. Philip Borsellino, Reese I. Krider, Raul E. Marquez, and Thomas A. Vida (all Medicine) published the study, "The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness."

About the study

The human brain controls everything from thoughts to actions through billions of neurons connected in a vast network. This network continually evolves and adapts through neuroplasticity, crucial for mental health and recovery from brain diseases. Dimethyltryptamine (DMT) is a powerful natural psychedelic molecule found not only as an endogenous molecule in human brains but also as a key psychoactive component in Ayahuasca, a traditional Amazonian brew used for centuries in healing rituals. DMT interacts with the brain's mood and cognition centers, suggesting its use could revolutionize treatments for conditions like depression, anxiety, and PTSD. Research into DMT spans from animal studies to human trials, revealing its profound effects on perception, cognition, and emotional well-being. This exploration is not just about understanding DMT's impact on the mind's landscape but also its ability to forge new neural pathways, enhance learning and memory, and aid in the recovery from brain injuries and neurodegenerative diseases like Alzheimer’s. With a keen focus on the mechanisms behind DMT's healing effects, this review points to a future where neurogenesis—growing new brain cells—could offer hope for combating a host of mental illnesses and neurodegenerative diseases. DMT may be a beacon of therapeutic potential in mental health and brain recovery.